Merck Walks Away From Revolution Medicines — But the Buyout Battle Is Now More Interesting
Merck Walks Away From Revolution Medicines — But the Buyout Battle Is Now More Interesting Merck’s decision to pause talks with Revolution Medicines has major implications for biotech deal-making in 2026. Why the talks cooled, what was really at stake, and why a bidding war could still erupt in oncology’s hottest niche. For weeks, biotech […]